Research ExplorerPublicationsBelantamab mafodotin: an important treatment option for vuln...

Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

Standard

Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma. / Mateos, Maria Victoria; Weisel, Katja; Terpos, Evangelos; Delimpasi, Sossana; Kastritis, Efstathios; Zamagni, Elena; Delforge, Michel; Ocio, Enrique; Katodritou, Eirini; Gay, Francesca; Larocca, Alessandra; Leleu, Xavier; Otero, Paula Rodriguez; Schjesvold, Fredik; Cavo, Michele; Dimopoulos, Meletios A.

In: HAEMATOLOGICA, Vol. 109, No. 7, 01.07.2024, p. 2337-2340.

Research output: SCORING: Contribution to journal › Letter › Research › peer-review

Harvard

Mateos, MV, Weisel, K, Terpos, E, Delimpasi, S, Kastritis, E, Zamagni, E, Delforge, M, Ocio, E, Katodritou, E, Gay, F, Larocca, A, Leleu, X, Otero, PR, Schjesvold, F, Cavo, M & Dimopoulos, MA 2024, 'Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma', HAEMATOLOGICA, vol. 109, no. 7, pp. 2337-2340. https://doi.org/10.3324/haematol.2023.284694

APA

Mateos, M. V., Weisel, K., Terpos, E., Delimpasi, S., Kastritis, E., Zamagni, E., Delforge, M., Ocio, E., Katodritou, E., Gay, F., Larocca, A., Leleu, X., Otero, P. R., Schjesvold, F., Cavo, M., & Dimopoulos, M. A. (2024). Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma. HAEMATOLOGICA, 109(7), 2337-2340. https://doi.org/10.3324/haematol.2023.284694

Vancouver

Mateos MV, Weisel K, Terpos E, Delimpasi S, Kastritis E, Zamagni E et al. Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma. HAEMATOLOGICA. 2024 Jul 1;109(7):2337-2340. https://doi.org/10.3324/haematol.2023.284694

Bibtex

@article{19b8bd354c61435ea628370dd23e9e80,
title = "Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma",
author = "Mateos, {Maria Victoria} and Katja Weisel and Evangelos Terpos and Sossana Delimpasi and Efstathios Kastritis and Elena Zamagni and Michel Delforge and Enrique Ocio and Eirini Katodritou and Francesca Gay and Alessandra Larocca and Xavier Leleu and Otero, {Paula Rodriguez} and Fredik Schjesvold and Michele Cavo and Dimopoulos, {Meletios A}",
year = "2024",
month = jul,
day = "1",
doi = "10.3324/haematol.2023.284694",
language = "English",
volume = "109",
pages = "2337--2340",
journal = "HAEMATOLOGICA",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "7",

}

RIS

TY - JOUR

T1 - Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

AU - Mateos, Maria Victoria

AU - Weisel, Katja

AU - Terpos, Evangelos

AU - Delimpasi, Sossana

AU - Kastritis, Efstathios

AU - Zamagni, Elena

AU - Delforge, Michel

AU - Ocio, Enrique

AU - Katodritou, Eirini

AU - Gay, Francesca

AU - Larocca, Alessandra

AU - Leleu, Xavier

AU - Otero, Paula Rodriguez

AU - Schjesvold, Fredik

AU - Cavo, Michele

AU - Dimopoulos, Meletios A

PY - 2024/7/1

Y1 - 2024/7/1

U2 - 10.3324/haematol.2023.284694

DO - 10.3324/haematol.2023.284694

M3 - Letter

C2 - 38385280

VL - 109

SP - 2337

EP - 2340

JO - HAEMATOLOGICA

JF - HAEMATOLOGICA

SN - 0390-6078

IS - 7

ER -